Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
about
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogsFitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1Estimating HIV-1 fitness characteristics from cross-sectional genotype dataA fossil record of zidovudine resistance in transmitted isolates of HIV-1Lack of evidence for changing virulence of HIV-1 in North America.The Effects of Population Size Histories on Estimates of Selection Coefficients from Time-Series Genetic Data.A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events.Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments.Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assayDecreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Impaired replication capacity of acute/early viruses in persons who become HIV controllers.Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionDrug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness.Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation.Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infectionOrigin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host.Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitnessFitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan.Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.Evolution of drug-resistant viral populations during interruption of antiretroviral therapyFluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.Lipid Peroxidation Correlates with HIVmRNA in Serodiscordant Heterosexual HIVpartners of Nigerian Origin.Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?
P2860
Q28344169-DF235B3F-CA49-4267-A1DB-D3F324D38DC2Q28477614-D11763DC-21B2-42BA-9753-C79DE453865FQ28544753-9F69A777-9212-43E1-9FBA-94E66D271913Q28775685-B7B69591-F4B3-4BFE-93D5-91D5C8585D10Q30367604-44ED14E6-E496-4FEC-8BB6-8A2977779129Q31123060-868E44A0-C486-4C6B-BB97-836634A4E6C7Q33604871-E54B1298-8406-442B-9D85-6B796A2E6455Q33643192-F2B2E0A7-DB08-4054-8406-C4505971CB21Q33737755-C17303F5-FC59-45E7-96FF-DF81F7BBF4B7Q33785915-E22ADA76-28E3-4E7E-AA09-9D3D3D2860B2Q33788743-C0084584-40D5-43E5-9DCD-8E50FC60CE76Q33811164-5EEA7685-DC18-412F-B7CB-D8BB8A1B7390Q33814927-EB520439-3405-4D11-A9B6-56E9AFC9077EQ33820365-5153EC39-3147-4309-A318-0A57CBED4BB8Q33826453-85097ACB-6371-4B11-BC62-D8BBD76FCF78Q33849423-2141C9D4-7010-446D-9896-F2C9E09DFCB3Q33872810-0DB66633-17F4-4C7D-B495-90D71470EE1BQ33884059-E777B704-B108-4674-9AFD-5F75EAE0D9C1Q33900459-3BF408C4-CB2A-486C-8E86-14CBED5C71B1Q33963989-49551717-A8FD-4D27-A98E-ED05BEFC0CF6Q33973857-99853547-D637-49C3-8B9F-9CCA471EB71BQ34012585-6C61EF65-B6A9-4025-A7E2-68545622B451Q34053505-4DD18104-6A2F-4ACF-9830-0FF98D00CF21Q34092679-AD49CAAB-8FD9-4523-9D26-4BBBB0173423Q34243486-45EDA41B-8985-4BA5-B928-4E346B9EFA5EQ34330667-0B24372B-4217-4F6B-B25A-2D335744F87FQ34342200-75A5BB0C-B0DA-46D8-8306-75B7381BE624Q34353398-70DF527F-D9C3-47FA-8D7F-195DF2AFCF08Q34434646-C005EFE9-AC7A-4413-B1D4-48EB98FD5B85Q34489422-7E414FD6-D0A4-44AA-B7F4-BFCBF4A58829Q34615228-E7905640-3D14-4084-9AE4-CC4CE42E29BDQ34651403-ECA7A1D2-0601-454C-A16C-3C56A1065FEAQ34717892-CB3A791D-EC32-474D-B1C7-F0127B24623CQ34719435-42B8AE0D-FCE2-4217-909B-4E241706356FQ34740940-464F0B9D-BB4F-44A4-9678-9B9E04E01EA7Q34803017-FFDC2B01-660A-48F7-BF09-4C90509D706CQ35077423-2DF9ABD0-6187-4888-BFE7-ADF01D13149CQ35156768-018D55A7-29A2-42AC-9098-500C345014D6Q35184285-C39053B6-7376-4E6D-8B6E-FC5A95DC97A9Q35959266-47348375-E8D3-4BF6-B5F0-C5E4537759D0
P2860
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Relative replicative fitness o ...... irus type 1 isolates in vitro.
@en
Relative replicative fitness o ...... irus type 1 isolates in vitro.
@nl
type
label
Relative replicative fitness o ...... irus type 1 isolates in vitro.
@en
Relative replicative fitness o ...... irus type 1 isolates in vitro.
@nl
prefLabel
Relative replicative fitness o ...... irus type 1 isolates in vitro.
@en
Relative replicative fitness o ...... irus type 1 isolates in vitro.
@nl
P2093
P2860
P1433
P1476
Relative replicative fitness o ...... irus type 1 isolates in vitro.
@en
P2093
P2860
P304
P407
P577
1998-05-01T00:00:00Z